ESCRS - FP04.06 - Clinical Outcomes Of Combined Cataract Surgery With Istent Inject® W Implantation Versus Cataract Surgery Alone In Patients With Open-Angle Glaucoma: Real Life Data In A Community-Based Outpatient Setting

Clinical Outcomes Of Combined Cataract Surgery With Istent Inject® W Implantation Versus Cataract Surgery Alone In Patients With Open-Angle Glaucoma: Real Life Data In A Community-Based Outpatient Setting

Published 2026 - 44th Congress of the ESCRS

Reference: FP04.06 | Type: Free paper | DOI: 10.82333/bsag-np42

Authors: Dr Fidan Aghayeva* 1 , Dr Abdelrahman Assaf 2 , A/Prof. Ines Lanzl 3

1Technical University of Munich,Munich,Germany;Chiemsee Eye Clinic,Prien on Chiemsee,Germany, 2Ophthalmology,Ulm University Eye Clinic,Ulm,Germany, 3Ophthalmology,Technical University of Munich,Munich,Germany;Chiemsee Eye Clinic,Prien on Chiemsee,Germany

Purpose

This study aims to evaluate and compare intraocular pressure (IOP) change and number of topical IOP-lowering medications after combined cataract surgery with iStent inject® W implantation versus cataract surgery alone in patients with open-angle glaucoma.

Setting

Retrospective comparative chart review

Methods

Retrospective data of 150 patients (150 eyes) with different types of open-angle glaucoma, who were naïve to any previous ocular procedure and underwent combined cataract surgery with iStent® W implantation (study group - 100 eyes) or cataract surgery alone (control group - 50 eyes), was performed. Study outcomes were median IOP change in the operated eye and the mean number of topical IOP-lowering medications at 3, 6 and 12 months after surgery.

Results

The median pre- and postoperative IOP in the study group at 6 and 12 months were 18.5 (16-20) mmHg, 14.5 (12-16) mmHg and 14.5 (12-16) mmHg, respectively. The median IOP change in iStent® W group was -4 (-6.75 to -2) mmHg at 12 months follow up. IOP reduction in the study group was statistically significantly larger than in the control group at 12 months (p<0.001). The higher the preoperative IOP level, the larger was the IOP-lowering effect at different follow-ups after combined surgery (p<0.001). We found a statistically significant difference between the mean number of IOP-lowering medications before and at 12 months after combined surgery (p<0.001), while control group showed no reduction in preoperative medications. 

Conclusions

This study shows a statistically significant IOP reduction at 12 months after combined cataract surgery with iStent® W implantation compared to insignificant IOP change after cataract surgery alone in glaucoma patients. iStent inject® W in combination with cataract surgery is associated with the reduction of topical IOP-lowering medications at 12 months follow-up. The higher the preoperative IOP in the operated eye, the larger the IOP-lowering effect after combined surgery at all follow-ups.